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Abstract: Pancreatic ductal adenocarcinoma (PDAC) is expected to soon become the second leading
cause of cancer related deaths in the United States. This may be due to the rising obesity prevalence,
which is a recognized risk factor for PDAC. There is great interest in deciphering the underlying
driving mechanisms of the obesity–PDAC link. Visceral adiposity has a strong correlation to certain
metabolic diseases and gastrointestinal cancers, including PDAC. In fact, our own data strongly
suggest that visceral adipose tissue inflammation is a strong promoter for PDAC growth and
progression in a genetically engineered mouse model of PDAC and diet-induced obesity. In this
review, we will discuss the relationship between obesity-associated adipose tissue inflammation and
PDAC development, with a focus on the key molecular and cellular components in the dysfunctional
visceral adipose tissue, which provides a tumor permissive environment.
Keywords: obesity; adipose tissue inflammation; pancreatic ductal adenocarcinoma
1. Obesity and Pancreatic Ductal Adenocarcinoma
Pancreatic cancer, of which pancreatic ductal adenocarcinoma (PDAC) accounts for the vast
majority, is an aggressive disease with an overall 5-year survival rate of ~8% [1]. Currently, as the third
leading cause of cancer mortality in both men and women, pancreatic cancer is expected to soon become
the second leading cause of cancer-related deaths in the United States [2]. One of the recognized risk
factors for PDAC and several other gastrointestinal cancers is obesity [3–8]. A recent analysis by the
National Institutes of Health reported that 16.9% of all PDAC cases in the Unites States are estimated
to be attributable to excess body weight (in comparison, the proportion of PDAC cases attributable to
cigarette smoking was 10.2%) [9]. Besides promoting tumorigenesis, obesity might also complicate the
treatment of established cancers [10], not only by altering the pharmacokinetics and pharmacodynamics
of administered anti-cancer drugs [11], but also by modulating the tumor microenvironment (TME) [12].
Notably, worse prognosis is reported in patients who are either overweight or obese at the time of PDAC
diagnosis [13,14]. Considering the current obesity pandemic, there is great interest in deciphering the
underlying biological basis of this compelling epidemiological link.
The mechanisms underlying the obesity–cancer link are likely multifactorial, with metabolic
perturbations and inflammation being the current research focus. Other mechanisms, such as alterations
in the gut microbiome, changes in gastrointestinal peptides, and sex hormones, certainly play an
important role as well. For example, obesity-associated insulin resistance and hormonal changes
(e.g., compensatory hyperinsulinemia and elevated insulin-like growth factors (IGFs)) are among the
various driving mechanisms postulated to explain the obesity–cancer link [15]. In accordance with
this notion, type 2 diabetes, hyperinsulinemia, and increased circulating IGF-1 are established risk
factors for pancreatic and other types of cancers [16–20]. In addition to the insulin/IGF axis, increasing
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attention has focused on adipose tissue (AT) dysfunction characterized by a pro-inflammatory state,
which can contribute not only to the pathogenesis of insulin resistance [21] but also to the development
and promotion of cancer. Utilizing a genetically engineered mouse model of PDAC and diet-induced
obesity, our own data suggest that inflammatory responses in the AT surrounding the pancreas is a
strong promotional factor for PDAC growth and progression [22]. AT inflammation associated with
increased abdominal adiposity, which involves various cellular and extracellular components (e.g.,
infiltrated macrophages and cytokines), can shape the peri-tumoral micro-environment favorable for
PDAC development, both locally and systemically. More detailed cellular and molecular characteristics
of dysfunctional and inflamed AT associated with the obese state, and their roles in tumor development,
will be discussed in the later sections.
2. The Role of Adipose Tissue Inflammation in Obesity-Promoted Tumor Development
2.1. Classification and Physiological Roles of AT
White adipose tissue (WAT), the most abundant type of AT in adult humans, stores excess energy
in the form of triglycerides, which can be mobilized via lipolysis to release fatty acids for usage by
other tissues. Based on anatomical locations, AT can also be organized into different types of depots:
Subcutaneous and visceral. These depots are heterogeneous with regard to their morphological,
molecular, and metabolic profiles [23], and exhibit major gender differences. Visceral adipose tissue
(VAT), which encompasses omental, mesenteric, and other intra-abdominal fat pads, is considered
of great relevance in obesity-related comorbidities, as increased VAT area is more closely associated
with metabolic dysfunction and cancer than subcutaneous fat [7,23–25]. Surgical removal of VAT
prior to high fat diet feeding is shown to prevent obesity-induced insulin resistance in mice [26].
Since VAT is in close proximity to digestive organs, including the pancreas, and is the primary source
of systemic and local chronic inflammation during obesity [27], it is particularly pertinent to the topics
covered in this review. For example, VAT (but not subcutaneous fat) and pancreatic fatty infiltration
are significantly correlated with pancreatic intraepithelial neoplasia (PanIN), the precursor lesions of
PDAC [28]. Interestingly, the increased PDAC incidence in obese conditional KrasG12D (KC) mice was
largely observed in male animals [29], which correlated with a greater expansion of VAT in obese male
mice, as compared to obese female mice that preferentially gained subcutaneous fat [22].
Besides being a key regulator of energy homeostasis, AT is regarded as an important endocrine
organ secreting various factors collectively known as “adipokines”, and growingly recognized as a
prominent immune site harboring macrophages and other types of immune cells. Overall, this dynamic
organ is composed of mature adipocytes and the “stromal-vascular fraction” comprising a mixture
of mesenchymal, hematopoietic, and endothelial cell types. Under homeostatic conditions, the cells
with diverse functional roles act cooperatively to support the metabolic and physiological functions
of the organ. Specifically, healthy AT maintains an anti-inflammatory phenotype characterized by
the secretion of anti-inflammatory adipocytokines (e.g., adiponectin) and enrichment of regulatory
immune cells, such as M2 macrophages, eosinophils, Th2 leukocytes, and myeloid-derived suppressor
cells that limit AT inflammation. In obesity, on the other hand, the regulatory anti-inflammatory
network in AT is disrupted and skewed to a pro-inflammatory state, with substantial changes in
adipokines and the number and function of AT immune cells (see next section), leading to sustained
chronic inflammation.
2.2. Obesity-Associated AT Inflammation
Chronic over-nutrition is manifested as adipose tissue expansion via hyperplasia (increase in
adipocyte numbers) and/or hypertrophy (enlargement of existing adipocytes). Adipocyte hyperplasia,
which occurs more readily in subcutaneous depots than in VAT, is normally associated with no/weak
inflammation and improved insulin sensitivity and therefore regarded as a “metabolically healthy”
expansion of AT. Conversely, visceral adipocyte hypertrophy, which is often associated with cellular
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stress, pro-inflammatory responses, and impaired insulin sensitivity, is recognized as unhealthy
pathological expansion and an important contributor to the obesity-related metabolic disorders [30].
When hypertrophic adipocytes are overloaded with lipids, they become hypoxic and undergo
stress responses and cell death, which are correlated with a pro-inflammatory secretome, increased
pro-inflammatory immune cell infiltration, and ectopic lipid deposition in other metabolically active
organs [31], each of which may contribute to progressive insulin resistance and the pathogenesis of
type 2 diabetes.
Adipocyte hypertrophy is associated with a shift in the adipokine secretion profile [32].
Specifically, there is a significant increase in the production of pro-inflammatory factors, such as
leptin, tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), monocyte chemoattractive protein-1
(MCP-1), and plasminogen activator inhibitor-1 (PAI-1). On the contrary, the release of adiponectin,
a major anti-inflammatory adipokine, is reduced with increased adiposity in response to AT
inflammation [33]. These adipocyte-derived mediators, which link adipocytes with adipose-resident
immune cells, lead to an altered composition of the adipose stromal-vascular fraction characterized
by reduced numbers of anti-inflammatory cells (e.g., eosinophils, T-regs, Th2 cells) and an increased
recruitment of pro-inflammatory Th1 cells, neutrophils, IFNγ-producing natural killer (NK) cells, and
monocytes/macrophages [34,35].
The detailed landscape of immune cell changes in AT during obesity is extremely complex and
virtually every immune cell type plays a role in obesity-associated metabolic diseases [36]. However, the
most prominent feature is monocyte infiltration and differentiation into pro-inflammatory macrophages,
which surround necrotic adipocytes and form the histological hallmark of AT inflammation called
“crown-like structures” [37]. AT macrophages (ATM), which can account for up to 50% of the cellular
content in the obese AT, are the primary source of pro-inflammatory cytokines (e.g., IL-6, TNF-α,
IL1-β), and have been shown to be centrally important in obesity-related metabolic dysfunction [38–41].
The increase in ATM abundance during obesity is crucial for exacerbating the inflammatory response
and is mainly caused by the recruitment of circulating bone marrow-derived monocytes through
an MCP-1 (CCL2)/CCR2- dependent mechanism [42–44]. While resident ATMs in the lean state
display an anti-inflammatory M2-polarized phenotype, obesity-associated ATM polarize towards
the pro-inflammatory M1 state in response to the disturbed immune and cytokine profile and other
environmental cues [35]. Interestingly, the oversimplified M1/M2 dichotomy is revised by the recent
discovery of the “metabolically-activated” type ATM, which is metabolically activated by excessive
saturated free fatty acids (FFAs), hyperinsulinemia, and hyperglycemia and is functionally distinct
from the classical M1 macrophage activated by bacterial challenge [45]. As mentioned above, it is
well established that AT inflammation and ATMs play a key role in the pathogenesis of metabolic
syndromes, mainly via secreted mediators. However, much less is known about their role in cancer,
especially PDAC.
Besides intrinsic danger signals, exogenous factors, such as gut microbiota-derived
pathogen-associated molecular patterns (PAMPs), are also implicated in the reprogramming of
immune cells toward pro-inflammatory subtypes in obese AT. Diet-induced obesity is associated
with a robust change in gut microbiota composition [46,47] and impaired intestinal barrier integrity,
correlating with an increased expression of pro-inflammatory cytokines in the AT [48,49]. Induced by
gut dysbiosis and leaky intestinal tight junctions, circulating levels of lipopolysaccharide (LPS;
a cell wall component of gram-negative bacteria) are found to be 2 to 3-fold higher in obese
humans and rodents as compared to their lean counterparts, a phenomenon known as “metabolic
endotoxemia” [50,51]. Elevated LPS levels in tissues, e.g., AT, can stimulate the innate immune
response by activating Toll-like receptor 4 (TLR4) on macrophages, leading to the induction of NF-κB
and pro-inflammatory cytokine production. Using germ-free mouse models, microbiota-derived
LPS has been shown to promote macrophage infiltration and M1 polarization in WAT, independent
of its role in regulating fat mass and glucose metabolism [52]. Additionally, mice fed a diet rich
in saturated lipids (lard) exhibited reduced insulin sensitivity, enhanced WAT inflammation, and
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increased activation of TLRs compared with mice fed a fish oil diet, and such phenotypic differences
were in part attributable to differences in gut microbiota composition [53]. These authors further
demonstrated that lard-induced ATM accumulation was mediated by adipocyte-produced MCP-1,
which was induced by microbial-derived factors through activation of TLR4 and the downstream
adaptor molecules, MyD88 and TIR-domain-containing adapter-inducing interferon-β (TRIF) [53].
Together, these data strongly suggest that intestinal microbiota contribute to changes in immune cell
function and AT inflammation during diet-induced obesity.
2.3. AT Inflammation in PDAC Development: The Molecular Links
Inflammation has long been associated with the development of cancer, including PDAC [54,55].
In a mouse model of obesity-promoted KrasG12D-driven pancreatic neoplasia, with obesity induced by
a high-fat high-calorie diet (HFCD), we observed a higher percentage of advanced PanIN lesions [56]
and increased PDAC incidence [29], accompanied by prominent signs of inflammatory immune
cell infiltration and elevation of pro-inflammatory cytokines in the pancreas [56] as well as the
peri-pancreatic AT [22]. In addition, deficiency in hormone-sensitive lipase (HSL) was associated
with AT inflammation and an acceleration of pancreatic cancer development in conditional KrasG12D
mice [57]. Cumulating evidence suggest a model in which diet-induced obesity leads to a robust
inflammatory response in visceral peri-pancreatic (or intra-pancreatic [28]) adipose tissue, which may
in turn promote inflammation and neoplastic progression in the neighboring pancreas, via soluble
factors secreted from adipocytes and/or adipose-infiltrating immune cells.
2.3.1. Leptin, Adiponectin, and Other Adipokines
Obese individuals are characterized by dramatic changes in adipokine production, and several of
these adipokine changes are associated with cancer development. The most prominent examples are the
increased levels of the pro-inflammatory leptin [58,59] and the reduced levels of the anti-inflammatory
adiponectin [60,61]. In several cancer models, leptin has been shown to promote cell proliferation,
migration, and invasion through activation of the Janus Kinase/Signal Transducer and Activator
of Transcription (JAK/STAT) pathway and the subsequent oncogenic phosphatidylinositol 3-kinase
(PI3K)/Akt and extracellular signal-regulated kinase (ERK) signaling, leading to increased expression
of inflammatory cytokines, angiogenic factors, and apoptotic proteins [61–64]. Adiponectin, on the
other hand, seems to exert antagonistic effects on tumor growth and progression through activation
of AMPK and protein tyrosine phosphatase 1B (PTP1B) [62,65]. However, the roles of circulating
leptin and adiponectin in PDAC development remain debatable [66], as some studies found higher
adiponectin/leptin ratios associated with pancreatic cancer [67,68]. Also, adiponectin transcription
is activated by nuclear receptor 5A2 (NR5A2), an important risk factor identified by a genome-wide
association study (GWAS) for pancreatic cancer [69]. Further, in our recent study using HSL deficient
conditional KrasG12D mice, decreased plasma leptin levels were observed in animals with advanced
PDAC [57], suggesting that leptin may not play a central mechanistic role in PDAC promoted by
AT inflammation. Besides systemic effects, adipokines generated by adjacent adipose tissue might
act locally directly on tumor cells [70,71] or modulate inflammation and immunity in the pancreatic
TME [72,73]. In that regard, it is noteworthy that lipocalin 2, a novel adipokine elevated in obesity
subjects [74], has been shown to promote obesity-associated PDAC by stimulating the pro-inflammatory
response in the TME [75].
2.3.2. Pro-Inflammatory Cytokines and Chemokines
Although the events initiating obesity-associated AT inflammation are not completely understood,
increased pro-inflammatory factors produced by adipocytes and infiltrating ATMs or other immune cells
in the dysfunctional AT create a systemic and local inflammatory environment. Some of these factors
elevated in obese subjects, such as tumor-promoting cytokines (e.g., TNF-α and IL-6) and monocyte
chemo-attractants (e.g., MCP-1 [76,77]), are implicated in PDAC development and progression.
Cells 2019, 8, 673 5 of 16
Increased expression of TNF-α is observed in obese AT [40,78], where this key pro-inflammatory
cytokine is thought to act locally as an autocrine or paracrine cytokine, since systemic TNF-α levels
do not necessarily reflect local changes in TNF-α concentrations [78,79]. A central role for TNF-α
in obesity-associated early pancreatic tumor promotion has been demonstrated by genetic deletion
of tumor necrosis factor receptor 1A (TNFR1) [80]. Functionally, TNF-α activates JNK and NF-κB
pathways, which are known to promote cell proliferation, invasion, and metastasis in various cancers,
including human PDAC, where NF-κB is constitutively activated [81–83]. NF-κB activation by TNF-α
can crosstalk with Notch signaling, which cooperates with oncogenic KRAS to promote PDAC
progression [84]. In addition, activated NF-κB can stimulate the production of chemokines (such
as MCP-1), by adipocytes and pre-adipocytes, leading to increased infiltration of pro-inflammatory
macrophages [85,86]. Further, NF-κB is a critical transcription factor of M1 macrophages, regulating
the expression of a variety of inflammatory genes, including those encoding IL-6, IL-1β, MCP-1, and
cyclooxygenase-2 (COX-2), shown to play important roles in obesity-related PDAC promotion [55].
Adipose expression of IL-6, another key modulator in inflammation-associated tumorigenesis [87,88], is
also upregulated in obese individuals [40,79]. IL-6 exerts its pro-tumorigenic and pro-invasive activities
through the activation of the STAT3 signaling pathway, which is essential for PDAC development
in the Kras-driven mouse model [89–91] and observed in human PDAC [92,93]. The effects of IL-1
are similar to those of TNF-α, and IL1β gene promoter single nucleotide polymorphisms (SNPs) are
linked with pancreatic cancer risk [94]. These key cytokines, whose production is increased with
obesity, also play critical roles in insulin resistance [78,95], adipokine regulation [96], and tumor stroma
modulation [12,97,98], indirectly influencing tumor cell growth. Importantly, these inflammatory
cytokines are associated with a poor prognosis in PDAC [99–101]. Overall, PDAC progression
is characterized by convergent activation of inflammatory transcriptional factors (i.e., NF-κB and
STAT3) [102], which can be stimulated by the pro-inflammatory cytokines whose secretion is markedly
enhanced in dysfunctional AT with increased adiposity (especially visceral adiposity).
2.3.3. Microbiota and Obesity-Promoted PDAC
The gut microbiome could be closely related to obesity-associated chronic inflammation though
TLR activation in the immune cell compartment, amplifying inflammatory responses and cytokine
production that can fuel tumor growth. Although the effects of gut microbiota on tumorigenesis
are mostly highlighted in other inflammation-driven, obesity-related gastrointestinal malignancies
(e.g., colon and liver cancer) [103], it is well-documented that dysbiosis of oral bacteria is associated
with increased risk for pancreatic cancer [104–106]. In experimental mouse models, LPS and TLR4
activation could enhance the severity of acute pancreatitis [107,108]. Also, ligation of TLRs, possibly
through NF-κB and MAP kinase pathways, are shown to exacerbate pancreatic fibro-inflammation
and accelerate Kras-driven pancreatic tumorigenesis [109–111]. However, less is known regarding
how obesity-induced gut dysbiosis and AT inflammation contribute to PDAC development. Based on
evidence linking the microbiome and inflammation-associated PDAC, and the notion that metabolic
endotoxemia can be a strong promoter of ATM infiltration and M1 polarization, gut bacteria are likely
to play a role in the interface of obesity, AT inflammation, and PDAC. Regardless, these interactions
need to be further tested in the context of obesity.
2.3.4. Other Factors Associated with AT Dysfunction in Obesity
Obesity and the inflammatory environment are typically associated with oxidative stress, another
important feature of dysfunctional AT, conferring genetic instability that can promote the acquisition of
oncogenic mutations in neighboring pancreatic cells [112,113]. The elevated oxidative stress can result
from enriched reactive oxygen species (ROS) and reactive nitrogen intermediates (RNIs) generated
by inflammatory cells, as well as mitochondrial dysfunction and lipid oxidation related to increased
release of surplus free fatty acids (FFA) and ectopic fat deposition. Interestingly, in our previous study
involving a mouse model of obesity-promoted PDAC, exome sequencing of advanced pancreatic
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intraepithelial neoplasia (PanIN) lesions identified numerous genetic variants unique to the HFCD (and
diet-induced obesity) group [29]. These genetic alterations are found in genes involved in oncogenic
pathways that are commonly implied in PDAC, including the insulin and PI3K/Akt pathway.
3. Interventional Perspectives
Based on the increasingly recognized link between obesity-induced AT inflammation and PDAC
development, AT inflammation has become an intriguing target for PDAC interception. There are
several possibilities to disrupt the promoting effects of (obesity-induced) AT inflammation on PDAC
growth and progression. Besides general health-promoting strategies aimed at reducing obesity (e.g.,
weight reduction), which certainly will positively impact AT inflammation, a detailed understanding of
the mechanistic link between AT inflammation and PDAC will lead to targeted approaches. Inhibiting
major pro-inflammatory mediators secreted by inflamed AT or blocking cytokine receptors in the
pancreas might be a promising approach. For example, anti-TNF-α antibodies and antagonists of IL-1
and IL6 receptors exhibit anti-tumor effects in pre-clinical models of PDAC [101,114–117]. However,
the blockade of these cytokines, although proven to be effective in treating other inflammatory diseases,
has had limited success in patients of metabolic diseases [118,119] or PDAC [120,121]. Given the
complexity of the immune cell changes and inflammatory responses in the AT during obesity, with the
multitude of inflammatory mediators, targeting single or even few cytokines simultaneously might not
be the best strategy. Blocking major pathways driving the inflammatory response in obese AT seems to
be preferable. An intriguing approach with clear and rapid translational potential is the use of Food
and Drug Administration (FDA)-approved drugs, e.g., statins.
Statins are lipid-lowering drugs that inhibit HMG-CoA reductase, which plays a central role
in the production of cholesterol. High cholesterol levels have been associated with cardiovascular
disease (CVD). Statins have been found to reduce CVD and mortality in those who are at high
risk [122]. The evidence is strong that statins are effective for treating CVD in the early stages of a
disease (secondary prevention) and in those at elevated risk but without CVD (primary prevention).
There is intense interest in repurposing statins in cancer [123]. A recent meta-analysis of 95 cohorts
including 1,111,407 individuals concluded that statin therapy has potential survival benefit for patients
with malignancy [124]. Several large studies support the preventive effect of statins in selected
cancers. Although some early epidemiologic studies reported no beneficial effects of statins on
PDAC risk [125–128], several recent studies associated statins with a significantly lower risk of cancer,
including PDAC [129–134]. In a large case-control study, statin use was associated with a 34% reduced
PDAC risk, with a stronger association in male subjects [133]. In a case control study of 408 patients
with PDAC and 816 matched controls, statin use was associated with reduced PDAC risk (odds ratio:
0.61; 95% CI: 0.43–0.88) [135]. In this study, the protective effect of statin was dose-dependent and
stronger in obese patients. Very recently, a meta-analysis of 26 studies containing more than 3 million
participants and 170,000 PDAC patients found a significant decrease in PDAC risk with statin use
(RR: 0.84; 95% CI: 0.73–0.97) [136]. In patients with chronic pancreatitis, statins lowered the risk of
progression and pancreatic cancer [137]. In addition, statins have been shown to improve survival
after resection of early PDAC, indicating a potential benefit for secondary prevention [138–140].
Besides their cholesterol lowering effects, statins are known to have anti-inflammatory
properties [141]. Statins attenuate AT inflammation in various human conditions and experimental
models [142–145]. The improvement of AT inflammation by statins correlated with a reduction of
inflammatory cell infiltration. In addition, statins have been found to decrease circulating MCP-1
levels, which are elevated in obese patients [76,146]. Importantly, statins elicited an anti-inflammatory
M2-polarization of macrophages [145,147]. In our own study using a genetically engineered mouse
model of pancreatic cancer promoted by diet-induced obesity, we found that oral administration of
simvastatin attenuated early pancreatic neoplastic progression [148], which was accompanied by a
marked reduction of inflammation in the VAT (unpublished; Figure 1).
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Figure 1. Representative histology of mesenteric adipose tissue of conditional KrasG12D mice fed an 
obesogenic high fat high calorie diet (HFCD) for 3 months supplemented without (upper panel) or 
with simvastatin (sim; lower panel). Quantification of crown-like structures demonstrates significant 
elevation of adipose tissue inflammation in obese HFCD-fed mice, which was abrogated by 
simvastatin (sim). *: p < 0.01 vs. CD; #: p < 0.01 vs. HFCD 
Mechanistically, statins inhibit 3-hydroxy-3-methlyglutaryl coenzyme (HMG-CoA) reductase, 
the rate-limiting enzyme that controls the conversion of HMG-CoA to mevalonic acid. Mevalonic 
acid is a precursor of isoprenoids, which are essential for the post-translational modification of small 
G-proteins, e.g., Ras homolog gene family, member A (RhoA), cell division control protein 42 
homolog (Cdc42), and Ras-related C3 botulinum toxin substrate 1 (Rac1), to attach to lipid 
membranes. Activation of Rho family members GTPases (guanosine triphosphate hydrolases) 
modulate the actin cytoskeleton, which has been shown to be an important regulator for macrophage 
polarization [149]. Our own unpublished data showed that lipophilic statins significantly attenuate 
pro-inflammatory signaling in macrophage cell lines through inhibition of the mevalonic acid/protein 
prenylation/actin cytoskeleton pathway. Besides their beneficial effects on AT inflammation, statins 
also have significant effects on PDAC cells [150–152]. Overall, statins show great promise for PDAC 
prevention/interception, in particular in the setting of obesity.  
4. Conclusion 
There is clear evidence that obesity increases the risk of pancreatic cancer. Obesity-induced AT 
inflammation is increasingly recognized as an important driver of the pathophysiologic process 
underlying the obesity–PDAC link. Dramatic changes in immune cell number and function in obese 
AT, especially VAT, with accompanying increased production of various pro-inflammatory 
cytokines may thereby promote the proliferation and survival of transformed cells in the adjacent 
pancreas. Although numerous immune cells have been shown to be involved in maintaining 
sustained AT inflammation in obesity, AT macrophages clearly play a central and critical role in 
orchestrating the inflammatory response. Given the importance of AT inflammation as a strong 
promotional driver of obesity-associated PDAC, strategies to inhibit obesity-induced AT 
inflammation are an intriguing approach. In this regard, the re-purposing of FDA-approved drugs 
aimed at reducing obesity-induced AT inflammation holds great translational significance. Recent 
epidemiologic data and preclinical evidence strongly suggest a role of statins, especially lipophilic 
statins, as promising drugs for PDAC prevention/interception. Besides their direct effects on PDAC 
cells, current data suggest that the anti-cancer properties of statins might at least partially include 
their anti-inflammatory effects on obese AT.  
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Figure 1. Representative histology of mesenteric adipose tissue of conditional KrasG12D mice fed an
obesogenic high fat high calorie diet (HFCD) for 3 months supplemented without (upper panel) or
with simvastatin (sim; lower panel). Quantification of crown-like structures demonstrates significant
elevation of adipose tissue inflammation in obese HFCD-fed mice, which was abrogated by simvastatin
(sim). *: p < 0.01 vs. CD; #: p < 0.01 vs. HFCD
Mechanistically, statins inhibit 3-hydroxy-3-methlyglutaryl coenzyme (HMG-CoA) reductase, the
rate-limiting enzyme that controls the conversion of HMG-CoA to mevalonic acid. Mevalonic acid is a
precursor of isoprenoids, which are essential for the post-translational modification of small G-proteins,
e.g., Ras homolog gene family, member A (RhoA), cell division control protein 42 homolog (Cdc42),
and Ras-related C3 botulinum toxin substrate 1 (Rac1), to attach to lipid membranes. Activation of Rho
family members GTPases (guanosine triphosphate hydrolases) modulate the actin cytoskeleton, which
has been shown to be an important regulator for macrophage polarization [149]. Our own unpublished
data showed that lipophilic statins significantly attenuate pro-inflammatory signaling in acrophage
cell lines through inhibition of the mevalonic acid/protein prenylation/actin cytoskeleton pathway.
Besides their beneficial effects on AT inflammation, statins also have significant effects on PDAC
cells [150–152]. Overall, statins show great promise for PDAC prevention/interception, in particular in
the setting of obesity.
4. Conclusions
There is clear evidence that obesity increases the risk of pancreatic cancer. Obesity-induced
AT inflammation is increasingly recognized as an important driver of the pathophy ologic process
underlying the obesity–PDAC link. Dramatic changes in immun cell number and function in obese
AT, especially VAT, with accompanying increased production of various pro-inflammatory cytokines
may ther by promote the proliferation and survival of transformed cells in the adjacent pancreas.
Al hough numerous immune c lls have b en shown to be inv lved in maintaining sustained AT
inflammation in obesity, AT macrophages learly play a central a d critical role in orchestrating the
inflammatory response. Give the importance of AT inflammation as strong promot onal driver
f ob sity-associated PDAC, strategies to inhibit obesity-induced AT inflamm tion are an intrigui
approach. In this regard, the r -purposing of FDA-approved drugs aimed at reducing obesity-in uced
AT inflammation holds great translational sign ficance. Recent epidemiologic data and preclinical
evid nce strongly sugges a role of statins, especially lipophilic st ins, as pr misin drugs for PDAC
prev nt n/interception. B sides th ir direct effects on PDAC cel s, current data suggest that the
anti-cancer properties of statins might at l ast partially include their anti-inflammatory effects on
obe e AT.
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